Victoria Bray

TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.

TL;DR: Entrectinib continued to demonstrate deep and durable responses and was well tolerated in pts with NTRK-fp solid tumors with or without baseline CNS metastases and in the safety population, most treatment-related adverse events were grade 1/2 and not serious.

TL;DR: A single item question asking about cognitive change has acceptable discrimination between patients with self-reported normal and low cognitive function when compared to other more comprehensive self-report measures of cognitive symptoms.

TL;DR: Existing resources, staff input and technical and logistical reasons often guided the ICP decisions, highlighting the need for in-depth engagement across all stakeholders for optimal implementation of ePRO ICPs.

TL;DR: Pre-CRT NLR and sustained NLR is associated with worse PFS outcomes in unresectable stage III NSCLC treated with CRT and durvalumab and remained independently prognostic for PFS on multivariate analysis (p = 0.04, p =-0.01) respectively.